6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04265027 (ClinicalTrials.gov)	February 20, 2018	7/2/2020	Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)	An Open Label, Randomised, Two Period, Crossover Study to Assess Bioavailability, Bioequivalence and S COMT Activity Between Two Active Pharmaceutical Ingredient Sources of Opicapone at Two Different Dosage Strengths (50 mg and 25 mg) After Single and Multiple Dose Administrations Under Fasting Conditions in Healthy Volunteers.	Parkinson Disease	Drug: 50 mg BIA 9 1067;Drug: 25 mg BIA9 1067;Drug: 50 mg Ongentys;Drug: 25 mg Ongentys	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	72	Phase 1	United Kingdom
2	NCT03116295 (ClinicalTrials.gov)	June 20, 2017	12/4/2017	Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone	A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects	Parkinson Disease	Drug: Opicapone (OPC)	Bial - Portela C S.A.	NULL	Completed	18 Years	55 Years	All	56	Phase 1	Germany
3	NCT03116308 (ClinicalTrials.gov)	November 21, 2014	12/4/2017	Effect of Food on Opicapone	Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects	Parkinson Disease	Drug: Opicapone (OPC)	Bial - Portela C S.A.	NULL	Completed	18 Years	45 Years	All	28	Phase 1	NULL